The answer appears to be ‘yes’ according to a survey by Mahendraratnam et al. (2019). After surveying subject matter experts that were senior representatives from payer organizations and pharmaceutical manufacturers on value-based pricing arrangements (VBA), they found:
More than 70% of VBAs implemented between 2014 and 2017 were not publicly disclosed. Furthermore, although consideration of VBAs as a coverage and payment tool is increasing, VBA implementation is relatively low, with manufacturers and payers reporting that approximately 33% and 60% of early dialogues translate into signed VBA contracts, respectively.
In short, VBAs are more common than we thought, but still not that common overall.
It has been great to have the updates condensed in a 1-3min read. It’d be even more convenient if you could offer the link to the original article so that readers can save 3-5 more clicks and searches for the abstract of the articles. Good work!